摘要
目的观察阿奇霉素治疗肺炎支原体肺炎的临床疗效及安全性。方法将 5 30例肺炎支原体肺炎患儿随机分成两组 :对照组 (n =2 10例 )予红霉素治疗 ,治疗组 (n =32 0例 )予阿奇霉素治疗 ,观察疗效及其不良反应并进行分析和总结。结果治疗组 32 0例 ,有效 2 97例 ,有效率 92 .8%,对照组 2 10例 ,有效 16 9例 ,有效率 80 .5 %,两组差异有显著性 (P <0 .0 1)。治疗组平均住院天数 (6 .30± 1.71)d ,对照组平均住院天数 (7.85± 2 .5 8)d ,两组差异有显著性 (P <0 .0 1)。治疗组胃肠道不良反应 2 2例 ,发生率 6 .9%,对照组胃肠道不良反应 4 1例 ,发生率 19.5 %,两组差异有显著性 (P <0 .0 1)。结论阿奇霉素治疗肺炎支原体肺炎具有疗效好、安全性高。
ObjectivesTo observe the therapeutic efficacy and safety of azithromycin in the treatment of mycoplasma pneumoniae. MethodsFive hundred and thirty children with mycoplasma pneumoniae were randomly divided into:①Treated group,azithromycin was given in 320 cases; and ②Control group,erythromycin was given in 210 cases. Their therapeutic efficacy and side effects were observed and results of study were analyzed and summarized.ResultsTwo hundred and ninety seven (92.8%)out of 320 cases were effective in treated group; while 169(80.5%)out of 210 cases were effective in control group, showing significant difference between both(P<0.01).The average duration of hospital stay in treated group(6.30±1.71)d was significantly shorter than that in control group(7.85±2.85)(P<0.01).The side effects of gastrointestinal tract occurred in 22 cases of treated group(6.9%), as compared with 41 cases(19.5%)in controls, a significant difference existed between two groups(P<0.01).ConclusionTreatment of mycoplasma pneumoniae with azithromycin has several advantages: better therapeutic efficacy, high safety, less side effects and shortened average duration of hospital stay, etc.
出处
《医学临床研究》
CAS
2003年第3期165-166,共2页
Journal of Clinical Research
